GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ascendis Pharma A/S (NAS:ASND) » Definitions » EBITDA Margin %

Ascendis Pharma A/S (Ascendis Pharma A/S) EBITDA Margin % : -49.15% (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Ascendis Pharma A/S EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Ascendis Pharma A/S's EBITDA for the three months ended in Dec. 2023 was $-73.8 Mil. Ascendis Pharma A/S's Revenue for the three months ended in Dec. 2023 was $150.2 Mil. Therefore, Ascendis Pharma A/S's EBITDA margin for the quarter that ended in Dec. 2023 was -49.15%.


Ascendis Pharma A/S EBITDA Margin % Historical Data

The historical data trend for Ascendis Pharma A/S's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ascendis Pharma A/S EBITDA Margin % Chart

Ascendis Pharma A/S Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1,572.65 -5,864.96 -4,687.96 -1,034.07 -154.16

Ascendis Pharma A/S Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -839.16 -283.51 -227.63 -275.46 -49.15

Competitive Comparison of Ascendis Pharma A/S's EBITDA Margin %

For the Biotechnology subindustry, Ascendis Pharma A/S's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ascendis Pharma A/S's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ascendis Pharma A/S's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Ascendis Pharma A/S's EBITDA Margin % falls into.



Ascendis Pharma A/S EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Ascendis Pharma A/S's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-448.384/290.859
=-154.16 %

Ascendis Pharma A/S's EBITDA Margin % for the quarter that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=-73.812/150.166
=-49.15 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ascendis Pharma A/S  (NAS:ASND) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Ascendis Pharma A/S EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Ascendis Pharma A/S's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Ascendis Pharma A/S (Ascendis Pharma A/S) Business Description

Traded in Other Exchanges
Address
Tuborg Boulevard 12, Hellerup, DNK, DK-2900
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates in North America, China, and Europe and derives the majority of its revenue from North America.

Ascendis Pharma A/S (Ascendis Pharma A/S) Headlines

From GuruFocus